Visterra Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 150

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $629K

  • Investors
  • 1

Visterra General Information

Description

Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The company designs and engineers antibody-based biological products for the treatment of non-infectious diseases that are not being adequately addressed, enabling healthcare providers and researchers to seek the significant unmet need for effective therapies.

Contact Information

Formerly Known As
Parasol Therapeutics
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 275 Second Avenue
  • 4th Floor
  • Waltham, MA 02451
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 275 Second Avenue
  • 4th Floor
  • Waltham, MA 02451
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visterra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 31-Mar-2025 $629K Completed Generating Revenue
9. Merger/Acquisition 31-Aug-2018 Completed Generating Revenue
8. Later Stage VC (Series C) 05-Oct-2017 Completed Generating Revenue
7. IPO 10-Feb-2017 Cancelled Generating Revenue
6. Grant 29-Sep-2015 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 15-May-2014 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 02-Dec-2013 Completed Startup
3. Debt - General 17-Sep-2010 Completed Startup
2. Seed Round 07-Dec-2009 $3.2M $5.2M Completed Startup
1. Seed Round 28-Jan-2008 $2M $2M Completed Startup
To view Visterra’s complete valuation and funding history, request access »

Visterra Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 32,447,072 $0.000100 $1 $1 1x $1 28.22%
Seed 6,178,926 $0.000100 $1 $1 1x $1 5.37%
To view Visterra’s complete cap table history, request access »

Visterra Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The co
Drug Discovery
Waltham, MA
150 As of 2025

South San Francisco, CA
 

Belfast, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visterra Competitors (74)

One of Visterra’s 74 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
CV6 Therapeutics Venture Capital-Backed Belfast, United Kingdom
Cellestia Venture Capital-Backed Basel, Switzerland
Oxford Biotherapeutics Private Equity-Backed Oxford, United Kingdom
Adrenomed Venture Capital-Backed Hennigsdorf, Germany
You’re viewing 5 of 74 competitors. Get the full list »

Visterra Patents

Visterra Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260337287-A1 Methods of using antibodies to a proliferation-inducing ligand (april) Pending 28-Mar-2025
WO-2026207341-A2 Methods of using antibodies to a proliferation-inducing ligand (april) Pending 28-Mar-2025
WO-2026207341-A3 Methods of using antibodies to a proliferation-inducing ligand (april) Pending 28-Mar-2025
US-20260028384-A1 Use of il-2 variant for treating kidney transplant rejection Pending 17-Apr-2024
WO-2025221954-A1 Use of il-2 variant for treating kidney transplant rejection Pending 17-Apr-2024 A61P37/06
To view Visterra’s complete patent history, request access »

Visterra Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visterra Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Allegheny Financial Group Asset Manager Minority
CTI Life Sciences Fund Venture Capital Minority
Cycad Group Venture Capital Minority
Flagship Pioneering Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Visterra FAQs

  • When was Visterra founded?

    Visterra was founded in 2008.

  • Where is Visterra headquartered?

    Visterra is headquartered in Waltham, MA.

  • What is the size of Visterra?

    Visterra has 150 total employees.

  • What industry is Visterra in?

    Visterra’s primary industry is Drug Discovery.

  • Is Visterra a private or public company?

    Visterra is a Private company.

  • What is Visterra’s current revenue?

    The current revenue for Visterra is .

  • How much funding has Visterra raised over time?

    Visterra has raised $629K.

  • Who are Visterra’s investors?

    Alexandria Venture Investments, Allegheny Financial Group, CTI Life Sciences Fund, Cycad Group, and Flagship Pioneering are 5 of 16 investors who have invested in Visterra.

  • Who are Visterra’s competitors?

    NGM Biopharmaceuticals, CV6 Therapeutics, Cellestia, Oxford Biotherapeutics, and Adrenomed are some of the 74 competitors of Visterra.

  • When was Visterra acquired?

    Visterra was acquired on 31-Mar-2025.

  • Who acquired Visterra?

    Visterra was acquired by Otsuka Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process